Roche has reported positive results from its Phase III REGENCY trial of Gazyva (obinutuzumab) for the treatment of lupus ...

Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...

Genentech, a member of Roche (RHHBY), announced that a detailed analysis of its Phase III REGENCY trial of Gazyva in people with active lupus ...

Atherosclerosis cardiovascular disease (ASCVD)-related mortality is higher in patients with lupus nephritis (LN) compared ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

The treatment procedures are required in the case of the severity of the condition. The patient then needs to go for a kidney ...

1 The purpose of ALMS was to demonstrate the superiority of mycophenolate mofetil (MMF) over intravenous cyclophosphamide for the induction of remission in patients with lupus nephritis.

1 More than 1.5 million people develop one of the most dangerous manifestations of SLE: lupus nephritis (LN), characterized by immune system induced inflammation of the kidneys. Within 10 years ...

Obinutuzumab could reshape the treatment of lupus nephritis, a life-threatening complication of lupus that has long lacked ...

The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for ...

The following is a summary of “Nomogram for predicting proliferative lupus nephritis in patients with low-level proteinuria,” ...

Conventional lupus nephritis (LN) treatment based on cyclophosphamide, steroids and, recently, mycophenolatemofetil has improved the outcome of the disease over the last 50 years, although failure ...